Highlights

Food & Drug Administration (FDA) mini-symposium

In 2024, Sylvie Freeman participated in an FDA mini-symposium on ‘The Methodology of Quantitating Blasts in Acute Leukemias for Response Assessments.’

This highlighted inconsistencies and practical challenges in methodologies used by clinical laboratories for reporting blast percentages.

Acute leukemia diagnostics panel

A panel of experts in acute leukemia diagnostics has been convened that includes the following representatives from our SWG:

  • Francesco Buccisano
  • Adriana Plesa
  • Leonor Arenillas
  • Sylvie Freeman

The panel has developed consensus criteria that align with updated clinical laboratory practice, with the aim of:

  • Facilitating the harmonization of reporting across institutions
  • Enhancing the reliability of response assessment in acute leukemia

The panel plans to submit a manuscript of this work during quarter two of 2025. The recommendations will be presented at a plenary educational session of the International Clinical Cytometry Society 2025 Conference.

Symposium on measurable residual disease (MRD)

The Third International Symposium on MRD in Haematological Malignancies will be held in Kiel, Germany, from September 25–27, 2025.

In addition to an overview of MRD methods and their standardization, the focus of the meeting will be on the clinical use of MRD in various hematological neoplasms in children and adults. The overall aim will be to reach a publishable consensus on certain MRD-related topics.

To this end, several representatives from our SWG have been invited to present the updated ‘state of the art’ in this field.

Share